Ju Ock Na

Ju Ock Na

Auto-generated profile, based on publicly available information

Ju Ock Na

Soonchunhyang university Hospital, Cheonan-si, Chungcheongnam-do, Republic of Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Tuberculosis and Respiratory Diseases
Verified
Journal Article
Open access
PDF file
HHHun-Gyu Hwang
Hun-Gyu Hwang
HLHo-Sung Lee
Ho-Sung Lee
JCJae-Sung Choi
Jae-Sung Choi
KSKi-Hyun Seo
Ki-Hyun Seo
YKYong-Hoon Kim
Yong-Hoon Kim
JNJu-Ock Na
Ju-Ock Na
Hwang HG, et al. Tuberc Respir Dis. 2013 Mar;74(3):111-119. http://dx.doi.org/10.4046/trd.2013.74.3.111

1 November 2014 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
YKYoung Il Kim
Young Il Kim
HKHyo Cheol Kang
Hyo Cheol Kang
HLHo Sung Lee
Ho Sung Lee
JCJae Sung Choi
Jae Sung Choi
KSKi Hyun Seo
Ki Hyun Seo
JNJuock Na
Juock Na

12 September 2024 in Chest
Verified
Journal Article
Closed access
JCJoon Young Choi
Joon Young Choi
CLChang-Hoon Lee
Chang-Hoon Lee
HJHyonsoo Joo
Hyonsoo Joo
YSYun Su Sim
Yun Su Sim
JLJaechun Lee
Jaechun Lee
YKYet Hong Khor
Yet Hong Khor

1 September 2018 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
CJChi Young Jung
Chi Young Jung
YCYeoung Hun Choe
Yeoung Hun Choe
SLSang Yeub Lee
Sang Yeub Lee
WKWoo Jin Kim
Woo Jin Kim
JLJong Deog Lee
Jong Deog Lee
JNJu Ock Na
Ju Ock Na
To use serological and multiplex polymerase chain reaction (PCR) assays to examine sputum samples from patients experiencing acute exacerbation of chronic obstructive pulmonary disease (AECOPD) for the presence of atypical pathogens, including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila. From September 2012 to February 2014, 341 patients with AECOPD attending outpatient clinics were enrolled as part of a randomized, double-blind, multicenter study. A commercial enzyme-linked immunosorbent assay was used to measure serum immunoglobulin M (IgM) and IgG antibody titers on the first day of the study and at 36 days post-enrollment. Multiplex PCR was used to test sputum samples for the presence of atypical pathogens. A urinary antigen test for L. pneumophila was performed on the first day. Nineteen patients (5.6%) showed serological evidence of acute infection with M. pneumoniae. Also, one and seven patients (2%) showed serological evidence of acute infection with C. pneumoniae and L. pneumophila, respectively. All DNA samples were negative for M. pneumoniae, C. pneumoniae, and L. pneumophila according to PCR. Only one urine sample was positive for L. pneumophila antigen, but serologic evidence was lacking. Serological testing suggested that infection by atypical pathogens during AECOPD was relatively uncommon. In addition, PCR provided no direct evidence of infection by atypical pathogens. Thus, atypical pathogens may not be a major cause of AECOPD in South Korea.

1 January 2015 in Tuberculosis and Respiratory Diseases
Verified
Journal Article
Open access
PDF file
MKMin Jin Kim
Min Jin Kim
SLSang Hyok Lim
Sang Hyok Lim
SHSu Jung Han
Su Jung Han
KCKang Hyug Choi
Kang Hyug Choi
SLSun Hyo Lee
Sun Hyo Lee
JNJu Ock Na
Ju Ock Na
Metastatic squamous cell carcinoma from a cancer of unknown primary (CUP) affecting the intrathoracic lymph node is very rare. We reported a case of metastatic squamous cell carcinoma in the hilar and interlobar lymph node from a patient with CUP and reviewed the associated literature. Abnormal mass in the right hilar area was incidentally detected. A chest computed tomography scan showed a 2.5-cm diameter mass in the right hilum that had changed little in size for 3 years. The patient underwent a right pneumonectomy and mediastinal lymph node dissection. A metastatic squamous cell carcinoma in the hilar and interlobar lymph nodes without a primary lung or other lesion was diagnosed. The patient received adjuvant chemotherapy for a diagnosis of T0N1M0 lung cancer.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
SYSunyoung Yoon
Sunyoung Yoon
TKTae-Hyung Kim
Tae-Hyung Kim
JNJu Ok Na
Ju Ok Na
KSKyeong-Cheol Shin
Kyeong-Cheol Shin
Chin Kook RheeChin Kook Rhee
Chin Kook Rhee
KYKwang-Ha Yoo
Kwang-Ha Yoo
The chronic obstructive pulmonary disease (COPD) assessment test (CAT) is a validated, eight-item questionnaire used to quantify the health status of patients. The aim of this study was to evaluate the usefulness of the CAT questionnaire as a tool to assess the response to treatment in acute exacerbations of COPD in an outpatient setting. A multicenter, phase 3 randomized controlled trial was conducted previously to examine the efficacy and safety of oral zabofloxacin for the treatment of COPD exacerbations. In the present post hoc analysis of the original study, patients with COPD exacerbation were categorized as responders or non-responders according to the respiratory symptoms persisting on day 10 (visit 3) of treatment. The CAT questionnaire was completed daily by patients at home from the initial visit to the second visit on day 5. Subsequently, the questionnaire was completed in the presence of a physician on days 10 (visit 3) and 36 (visit 4). Multivariate regression analysis was performed to determine the association between CAT scores and the therapeutic response. The CAT scores decreased more rapidly in responders compared to non-responders during the first 5 days (23.3-20.4 vs. 23.5-22). Among responders, patients with higher severity of illness also revealed higher CAT scores on the first day of an exacerbation (mild, 19.8; moderate, 21.4; severe, 23.8; very severe, 28.6). Multivariate analysis revealed that a change in the CAT score during the first 3 days influenced the therapeutic response. A significant decrease in scores in the domains of sputum production, chest tightness, and activities of daily living was seen among responders. Early improvement in CAT scores may be associated with a more favorable response to the treatment of COPD exacerbations. ClinicalTrials.gov Identifier: NCT01658020. Clinical Research Information Service Identifier: KCT0000532.